9. Imaging AD Progression

10. Amyloid Imaging Agents

11. Potential Clinical Roles for Amyloid Imaging Presented at SNMMI 2014

12. Longitudinal Amyloid PET in Patients With MCI

13. Presence of Brain Amyloid and Accelerated Cognitive Decline

14. Aβ Burden in People With Subjective Memory Complaints

15. More Complex Clinical Scenarios

16. Late-life Depression and Amyloid Accumulation in MCI

17. Post-stroke Dementia

18. Conclusions

21. Amyloid PET Imaging

22. Amyloid PET Tracers

23. A Negative Florbetaben PET Scan Reliably Excludes Amyloid Pathology as Confirmed by Histopathology

24. Prevalence of Aβ PET Positivity Across Dementia Syndromes

25. Prevalence of Aβ PET Positivity Across Dementia Syndromes (cont)

26. Imaging MCI With A Second-Generation Tracer

27. Diagnostic Value of Amyloid Imaging in Early-Onset Dementia

28. Amyloid PET Has Greater Clinical Impact Than FDG PET in the Differential Diagnosis of AD and FTD

29. Conclusions

31. Vascular Risk Factors Impact Cognition Independent of PiB PET and MRI Measures of AD and Vascular Brain Injury

32. Existing Thresholds for PiB Positivity Are Too High

33. Physical Activity Modifies Alzheimer Biomarkers in Preclinical AD

34. Imaging of Tau Pathology in Patients with Non-AD Tauopathies

35. Abbreviations

36. References

37. References (cont)

38. References (cont)

39. References (cont)

40. References (cont)